Report: Ratiopharm may be up for sale
FRANKFURT, Germany European generic powerhouse Ratiopharm may be placed on the sales bloc, Reuters reported over the weekend, citing sources close to the matter.
The sale may be part of a financial rescue package for German tycoon Adolf Merckle. The German newspaper Suedwest Presse had reported on its web site Friday that the sale of Ratiopharm was likely unavoidable, citing the head of Ratiopharm’s work council Odo Maxein. Maxein had been hoping for a takeover of Ratiopharm by a strategic investor such as Pfizer, the paper reported.
The Ratiopharm Group has 5,417 employees worldwide, including 2,846 in Germany, according to the company’s web site.
KV subsidiary hydromorphone hydrochloride tablets
ROCKVILLE, Md. A subsidiary of KV Pharmaceutical has recalled a lot of hydromorphone hydrochloride 2 mg tablets due to the possibility of oversized tablets, the Food and Drug Administration announced Tuesday.
Ethex Corporation and the FDA have notified healthcare professionals of the recall. The FDA that the oversized pills may lead to improper dosage, thus increasing the risk of adverse side affects associated with the drug, including difficulty breathing, low blood pressure and sedation.
The recalled tablets are round and blue, with a script “E” on one side and a “2” on the other. The recalled lot number is 90219, with an expiration date of March 2010 and the NDC number 58177-0620-04.
The tablets are a generic version of Purdue Pharma?s Dilaudid and used to treat severe pain.
Eli Lilly signs $497 million deal for dirucotide
NEW YORK Eli Lilly & Co. may get some relief from its drying pool of patent-protected drugs.
The Indianapolis drug maker has signed an agreement worth $497 million with biotech firm BioMS Medical Corp. for the drug dirucotide, a treatment for multiple sclerosis.
Expiring patents on Lilly drugs place nearly $10 billion of the company’s sales under threat.